BiotechTube

avatrombopag + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia Associated With Chronic Liver Disease

Conditions

Thrombocytopenia Associated With Chronic Liver Disease

Trial Timeline

Jul 1, 2014 → Apr 1, 2015

NCT ID
NCT02227693

About avatrombopag + Placebo

avatrombopag + Placebo is a phase 2 stage product being developed by Eisai for Thrombocytopenia Associated With Chronic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02227693. Target conditions include Thrombocytopenia Associated With Chronic Liver Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02227693Phase 2Completed

Competing Products

20 competing products in Thrombocytopenia Associated With Chronic Liver Disease

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
41
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
44
Placebo + LusutrombopagShionogiPhase 2
52
LusutrombopagShionogiPhase 2
52
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
52
avatrombopagEisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
77
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
52
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
77
Avatrombopag + Placebo + Standard of careEisaiPhase 3
77
RomiplostimKyowa KirinPhase 1/2
41
Romiplostim + PlaceboKyowa KirinPhase 3
77
Romiplostim (AMG-531)Kyowa KirinPhase 2
52
Romiplostim and danazolKyowa KirinPhase 2
52
ONO-7746Ono PharmaceuticalPhase 1
33
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
TPO-RA (Herombopag) + TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)Jiangsu Hengrui MedicinePhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85